{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:49:33Z","timestamp":1793659773522,"version":"4.5.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41409-025-02539-9","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:28:10Z","timestamp":1743121690000},"page":"559-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma"],"prefix":"10.1038","volume":"60","author":[{"given":"Marta","family":"Canelo-Vilaseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Sabbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cristinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-3550","authenticated-orcid":false,"given":"Sophie","family":"Caillat-Zucman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":false,"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"2539_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu S, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"2539_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl J Med. 2017;377:2531\u201344.","journal-title":"N. Engl J Med"},{"key":"2539_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl J Med. 2019;380:45\u201356.","journal-title":"N. Engl J Med"},{"key":"2539_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large bcell lymphoma (zuma-1): a single-arm, multicenter, phase 1-2 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"2539_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"J Abramson","year":"2020","unstructured":"Abramson J, Palomba L, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2539_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2020;382:1331\u201342.","journal-title":"N. Engl J Med"},{"key":"2539_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0789-z","volume":"21","author":"P Strati","year":"2019","unstructured":"Strati P, Neelapu S. Chimeric Antigen Receptor-engineered T cell therapy in Lymphoma. Curr Oncol Rep. 2019;21:38.","journal-title":"Curr Oncol Rep"},{"key":"2539_CR8","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"L Nastoupil","year":"2020","unstructured":"Nastoupil L, Jain M, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"2539_CR9","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu Z-H, Curran K, Laetsch T, Locke F, Rouce R, et al. Real world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"2539_CR10","first-page":"18","volume":"39","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Bachy E, Di Blasi R, Cartron G, Beauvais D, Le Bras F, et al. First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, a French real-life database for CAR-T cells in hematologic malignancies. Hematological Oncol. 2021;39:18.","journal-title":"Hematological Oncol"},{"key":"2539_CR11","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140:2584\u201393.","journal-title":"Blood"},{"key":"2539_CR12","first-page":"349","volume":"140","author":"W Bethge","year":"2022","unstructured":"Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140:349\u201358.","journal-title":"Blood"},{"key":"2539_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2022.280805","volume":"108","author":"M Kwon","year":"2023","unstructured":"Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica 2023;108:110\u201321.","journal-title":"Haematologica"},{"key":"2539_CR14","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"R Gardner","year":"2017","unstructured":"Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017;129:3322\u201331.","journal-title":"Blood"},{"key":"2539_CR15","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607\u201315.","journal-title":"Blood Adv"},{"key":"2539_CR16","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"M Jain","year":"2021","unstructured":"Jain M, Zhao H, Wang H, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 2021;137:2621\u201333.","journal-title":"Blood"},{"key":"2539_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/PAS.0000000000001834","volume":"46","author":"C Laurent","year":"2022","unstructured":"Laurent C, Syrykh C, Hamon M, Ad\u00e9la\u00efde J, Guille A, Escudi\u00e9 F, et al. Resistance of B-cell lymphomas to CAR T-cell therapy is associated with genomic tumor changes which can result in transdifferentiation. Am J Surg Pathol. 2022;46:742\u201353.","journal-title":"Am J Surg Pathol"},{"key":"2539_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Jain M, Smith E. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large b-cell lymphoma and multiple myeloma. Transplant Cell Ther. 2023;29:418\u201328.","journal-title":"Transplant Cell Ther"},{"key":"2539_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","volume":"4","author":"R Awasthi","year":"2020","unstructured":"Awasthi R, Pacaud L, Waldron E, Tam CS, J\u00e4ger U, Borchmann P, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL. Blood Adv. 2020;4:560\u201372.","journal-title":"Blood Adv"},{"key":"2539_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1182\/blood-2023-186478","volume":"142","author":"E Galli","year":"2023","unstructured":"Galli E, Battaglia A, Fossati M, Pansini I, Bellesi S, Buzzonetti A, et al. High levels of circulating granulocytic myeloid-derived suppressor cells (G-MDSCs) predict failure of CD19-targeting CAR-T cell therapy. Blood 2023;142:1015\u20137.","journal-title":"Blood"},{"key":"2539_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"J Brudno","year":"2018","unstructured":"Brudno J, Kochenderfer J. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"key":"2539_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappel","year":"2023","unstructured":"Cappel KM, Kochenderfer J. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"2539_CR23","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"C Turtle","year":"2016","unstructured":"Turtle C, Hanafi L, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.","journal-title":"Sci Transl Med"},{"key":"2539_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM195709122571102","volume":"157","author":"ED Thomas","year":"1957","unstructured":"Thomas ED, Lochte HL, Lu WC, Freebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl J Med. 1957;157:491\u20136.","journal-title":"N. Engl J Med"},{"key":"2539_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","volume":"49","author":"ED Thomas","year":"1977","unstructured":"Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511\u201333.","journal-title":"Blood"},{"key":"2539_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0308-2261(83)80003-4","volume":"12","author":"G Santos","year":"1983","unstructured":"Santos G. History of bone marrow transplantation. Clin Haematol. 1983;12:611\u201339.","journal-title":"Clin Haematol"},{"key":"2539_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier B. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014;124:344\u201353.","journal-title":"Blood"},{"key":"2539_CR28","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2539_CR29","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","volume":"3","author":"JB Langenhorst","year":"2019","unstructured":"Langenhorst JB, van Kesteren C, van Maarseveen EM, Dorlo TPC, Nierkens S, Lindemans CA, et al. Fludarabine exposure in the conditioning prior to allogeneic hematopoetic cell transplantation predicts outcomes. Blood Adv. 2019;3:2179\u201387.","journal-title":"Blood Adv"},{"key":"2539_CR30","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.4049\/jimmunol.139.5.1379","volume":"139","author":"EB Bell","year":"1987","unstructured":"Bell EB, Sparshott SM, Drayson MT, Ford WL. The stable and permanent expansion of functional T lymphocytes in athymic nude rats after a single injection of mature T cells. J Immunol. 1987;139:1379\u201384.","journal-title":"J Immunol"},{"key":"2539_CR31","doi-asserted-by":"publisher","first-page":"9547","DOI":"10.1158\/0008-5472.CAN-05-1175","volume":"65","author":"L Wang","year":"2005","unstructured":"Wang L, Shu S, Plautz G. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 2005;65:9547\u201354.","journal-title":"Cancer Res"},{"key":"2539_CR32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159\u201366.","journal-title":"J Natl Cancer Inst"},{"key":"2539_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850\u20134.","journal-title":"Science"},{"key":"2539_CR34","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Sherry R, Hughes MS, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233\u20139.","journal-title":"J Clin Oncol"},{"key":"2539_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laertsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl J Med. 2018;378:439\u201348.","journal-title":"N. Engl J Med"},{"key":"2539_CR36","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1182\/blood-2019-124492","volume":"134","author":"C Andreadis","year":"2019","unstructured":"Andreadis C, Tam C, Borchmann P, Jaeger U, McGuirk JP, Holte G, et al. Correlation of bridging and lymphodepleting chemotherapy with clinical outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma treated with Tisagenlecleucel. Blood 2019;134:2883.","journal-title":"Blood"},{"key":"2539_CR37","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023;141:1675\u201384.","journal-title":"Blood"},{"key":"2539_CR38","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2023","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2023;399:2294\u2013308.","journal-title":"Lancet"},{"key":"2539_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28:325\u201332.","journal-title":"Nat Med"},{"key":"2539_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cellimm.2009.11.011","volume":"261","author":"ML Salem","year":"2010","unstructured":"Salem ML, El-Naggar SA, Cole DJ. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol. 2010;261:134\u201343.","journal-title":"Cell Immunol"},{"key":"2539_CR41","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Finkelstein S, Klebanoff C, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 T cells. JEM. 2005;202:907\u201312.","journal-title":"JEM"},{"key":"2539_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.coi.2009.02.004","volume":"21","author":"P Muranski","year":"2009","unstructured":"Muranski P, Restifo N. Adoptive immunotherapy of cancer using CD4+ T cells. Curr Opin Immunol. 2009;21:200\u20138.","journal-title":"Curr Opin Immunol"},{"key":"2539_CR43","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14712598.2021.1857361","volume":"21","author":"N Bechman","year":"2021","unstructured":"Bechman N, Maher J. Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy \u2013 what are we doing; where are we going? Expert Opin Biol Ther. 2021;21:627\u201337.","journal-title":"Expert Opin Biol Ther"},{"key":"2539_CR44","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 2015;125:3905\u201316.","journal-title":"Blood"},{"key":"2539_CR45","doi-asserted-by":"publisher","first-page":"e99211","DOI":"10.1371\/journal.pone.0099211","volume":"9","author":"LA Hanafi","year":"2014","unstructured":"Hanafi LA, Gauchat D, Godin-Ethier J, Possama\u00ef D, Duvignaud JB, Leclerc D, et al. Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome mediated degradation mechanism. PLoS ONE. 2014;9:e99211.","journal-title":"PLoS ONE"},{"key":"2539_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S1734-1140(09)70098-2","volume":"61","author":"K Bryniarski","year":"2009","unstructured":"Bryniarski K, Szczepanik M, Ptak M, Zemelka M, Ptak W. Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol Rep. 2009;61:550\u20137.","journal-title":"Pharmacol Rep"},{"key":"2539_CR47","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","volume":"71","author":"G Schiavoni","year":"2011","unstructured":"Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergized with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;71:768\u201378.","journal-title":"Cancer Res"},{"key":"2539_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"N Restifo","year":"2018","unstructured":"Restifo N, Dudley M, Rosenberg S. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2018;12:269\u201381.","journal-title":"Nat Rev Immunol"},{"key":"2539_CR49","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.ymthe.2020.06.025","volume":"28","author":"P Innamarato","year":"2020","unstructured":"Innamarato P, Kodumudi K, Asby S, Schachner B, Hall M, Mackay A, et al. Reactive myelopoiesis triggered by lymphodepleting chemotherapy limits. Mol Ther. 2020;28:2252\u201370.","journal-title":"Mol Ther"},{"key":"2539_CR50","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"J Kochenderfer","year":"2017","unstructured":"Kochenderfer J, Somerville R, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 Levels. J Clin Oncol. 2017;35:1803\u201313.","journal-title":"J Clin Oncol"},{"key":"2539_CR51","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/ijms24065688","volume":"24","author":"V Wittibschlager","year":"2023","unstructured":"Wittibschlager V, Bacher U, Seipel K, Porret N, Wiedemann G, Haslebacher C, et al. CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int J Mol Sci 2023;24:5688.","journal-title":"Int J Mol Sci"},{"key":"2539_CR52","first-page":"2523","volume":"5","author":"F Ayuk","year":"2021","unstructured":"Ayuk F, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, et al. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood 2021;5:2523\u20137.","journal-title":"Blood"},{"key":"2539_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cpt.2561","volume":"112","author":"K Ogasawara","year":"2022","unstructured":"Ogasawara K, Lymp J, Mack T, Dell\u2019Aringa J, Huang CP, Smith J, et al. In vivo cellular expansion of of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma. Clin Pharm Ther. 2022;112:81.","journal-title":"Clin Pharm Ther"},{"key":"2539_CR54","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Rivi\u00e8re I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817\u201328.","journal-title":"Blood"},{"key":"2539_CR55","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood 2019;134:2361\u20138.","journal-title":"Blood"},{"key":"2539_CR56","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","volume":"6","author":"V Fabrizio","year":"2022","unstructured":"Fabrizio V, Boelens J, Mauguen A, Baggott C, Prabhu S, Egeler E, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6:1961\u20138.","journal-title":"Blood Adv"},{"key":"2539_CR57","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"J Kochenderfer","year":"2010","unstructured":"Kochenderfer J, Wilson W, Janik J. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099\u2013102.","journal-title":"Blood"},{"key":"2539_CR58","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709.","journal-title":"Blood"},{"key":"2539_CR59","doi-asserted-by":"publisher","first-page":"e122627","DOI":"10.1172\/jci.insight.122627","volume":"5","author":"MB Geyer","year":"2019","unstructured":"Geyer MB, Rivi\u00e8re I, S\u00e9n\u00e9chal B, Wang X, Wang Y, Purdon TJ, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL. JCI Insight. 2019;5:e122627.","journal-title":"JCI Insight"},{"key":"2539_CR60","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"A Hirayama","year":"2019","unstructured":"Hirayama A, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 2019;133:1876\u201387.","journal-title":"Blood"},{"key":"2539_CR61","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"J Brudno","year":"2020","unstructured":"Brudno J, Lam N, Venasse D. Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26:270\u201380.","journal-title":"Nat Med"},{"key":"2539_CR62","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"J Park","year":"2018","unstructured":"Park J, Riviere I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-Term Follow-up of CD19 CAR Therapy in acute lymphoblastic leukemia. N. Engl J Med. 2018;378:449\u201359.","journal-title":"N. Engl J Med"},{"key":"2539_CR63","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","volume":"6","author":"L Dekker","year":"2022","unstructured":"Dekker L, Calkoen F, Jiang Y, Blok H, Veldkamp SR, De Koning C, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022;6:1969\u201376.","journal-title":"Blood Adv"},{"key":"2539_CR64","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","volume":"7","author":"M Scordo","year":"2023","unstructured":"Scordo M, Flynn J, Gonen M, Devlin SM, Parascondola A, Tomas AA, et al. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023;7:5579\u201385.","journal-title":"Blood Adv"},{"key":"2539_CR65","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jtct.2022.08.002","volume":"28","author":"RT Maziarz","year":"2022","unstructured":"Maziarz RT, Diaz A, Miklos DB, Shah NN. Perspective: an International Fludarabine shortage: supply chain issues impacting transplantation and immune effector cell therapy delivery. Transpl Cell Ther. 2022;28:723\u20136.","journal-title":"Transpl Cell Ther"},{"key":"2539_CR66","first-page":"1329850","volume":"14","author":"D F Filioglou","year":"2023","unstructured":"F Filioglou D, Husnain M, Khurana S, Simpson RJ, Katsanis E. Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine? Font Immunol. 2023;14:1329850.","journal-title":"Font Immunol"},{"key":"2539_CR67","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","volume":"33","author":"G Ghilardi","year":"2022","unstructured":"Ghilardi G, Chong E, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol. 2022;33:916\u201328.","journal-title":"Ann Oncol"},{"key":"2539_CR68","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ajh.27069","volume":"98","author":"S Ong","year":"2023","unstructured":"Ong S, Pak S, Mei M, Wang Y, Popplewell L, Baird JH, et al. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. Am J Hematol. 2023;98:1751\u201361.","journal-title":"Am J Hematol"},{"key":"2539_CR69","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"D Porter","year":"2015","unstructured":"Porter D, Hwang WT, Frey N, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.","journal-title":"Sci Transl Med"},{"key":"2539_CR70","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","volume":"8","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, et al. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 2024;8:653\u201366.","journal-title":"Blood Adv"},{"key":"2539_CR71","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.2147\/OTT.S198567","volume":"12","author":"S Li","year":"2019","unstructured":"Li S, Xue L, Wang M, Qiang P, Xu H, Zhang X, et al. Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. Onco Targets Ther. 2019;12:5627\u201338.","journal-title":"Onco Targets Ther"},{"key":"2539_CR72","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11912-023-01404-6","volume":"25","author":"S Green","year":"2023","unstructured":"Green S, Schultz L. Rational alternatives to fludarabine and cyclophosphamide-based pre-CAR lymphodepleting regimens in the pediatric and young adult B-ALL setting. Curr Oncol Rep. 2023;25:841\u20136.","journal-title":"Curr Oncol Rep"},{"key":"2539_CR73","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1097\/MPH.0000000000002668","volume":"45","author":"A Foti","year":"2023","unstructured":"Foti A, Stein D, Seidel D. Clofarabine for Lymphodepletion before CAR-T-Cell Infusion: A brief Case Report. J Pedriatr Hematol Oncol. 2023;45:e551\u2013e554.","journal-title":"J Pedriatr Hematol Oncol"},{"key":"2539_CR74","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, et al. Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 2023;14:1303935.","journal-title":"Front Immunol"},{"key":"2539_CR75","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"2539_CR76","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","volume":"55","author":"E Galli","year":"2020","unstructured":"Galli E, Allain V, Di Blasi R, Bernard S, Vercellino L, Morin F, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma. Bone Marrow Transpl. 2020;55:2347\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2539_CR77","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","volume":"57","author":"R Lievin","year":"2023","unstructured":"Lievin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impct on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transpl. 2023;57:431\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2539_CR78","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259\u201375.","journal-title":"Ann Oncol"},{"key":"2539_CR79","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.seminhematol.2023.02.003","volume":"60","author":"J Gea-Banacloche","year":"2023","unstructured":"Gea-Banacloche J. Infectious complications of Chimeric Antigen Receptor (CAR) T-Cell therapies. Semin Hematol. 2023;60:52\u201358.","journal-title":"Semin Hematol"},{"key":"2539_CR80","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"K Hay","year":"2017","unstructured":"Hay K, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood 2017;130:2295\u2013306.","journal-title":"Blood"},{"key":"2539_CR81","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","volume":"25","author":"KL Lowe","year":"2018","unstructured":"Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 2018;25:176\u201391.","journal-title":"Gene Ther"},{"key":"2539_CR82","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"C Ramos","year":"2020","unstructured":"Ramos C, Grover N, Beaven A, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38:3794\u2013804.","journal-title":"J Clin Oncol"},{"key":"2539_CR83","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","volume":"8","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, et al. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024;8:802\u201314.","journal-title":"Blood Adv"},{"key":"2539_CR84","doi-asserted-by":"publisher","first-page":"969660","DOI":"10.3389\/fimmu.2022.969660","volume":"13","author":"C Qu","year":"2022","unstructured":"Qu C, Zou R, Wang P, Zhu Q, Kang L, Ping N, et al. Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients. Front Immunol 2022;13:969660.","journal-title":"Front Immunol"},{"key":"2539_CR85","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","volume":"132","author":"R Benjamin","year":"2018","unstructured":"Benjamin R. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood 2018;132:896.","journal-title":"Blood"},{"key":"2539_CR86","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2023-189196","volume":"142","author":"FL Locke","year":"2023","unstructured":"Locke FL, Munoz JL, Tees MT, Lekakis LJ, Eradat HA, de Vos S, et al. ALLO-647 for lymphodepletion in the allogeneic CAR T setting: safety experience with ALLO-501\/501A in patients (pts) with relapsed\/refractory (r\/r) large B-Cell and follicular lymphomas. Blood 2023;142:2095.","journal-title":"Blood"},{"key":"2539_CR87","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/2767-9764.CRC-22-0175","volume":"2","author":"S Dupouy","year":"2022","unstructured":"Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, et al. Clinical pharmacology and determinants of response to UCART19, an allogeneic anti-CD19 CAR-T cell product, in adult B-cell acute lymphoblastic leukemia. Cancer Res Commun. 2022;2:1520\u201331.","journal-title":"Cancer Res Commun"},{"key":"2539_CR88","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1182\/blood-2023-186570","volume":"142","author":"J Abramson","year":"2023","unstructured":"Abramson J, Ramakrishnan A, Alfonso Pierola A, Braunschweig I, Cartron G, Thieblemeont C, et al. Preliminary results of Nathali-01: a first-in-human phase I\/IIa study of UCART20x22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R\/R) non-Hodgkin Lymphoma (NHL). Blood 2023;142:2110\u20132.","journal-title":"Blood"},{"key":"2539_CR89","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier J, Bezerra E, Hirayama A, Fiorenza S, Sheih A, Chou CK, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 2021;137:323\u201335.","journal-title":"Blood"},{"key":"2539_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004483","volume":"10","author":"EM Holland","year":"2022","unstructured":"Holland EM, Molina JC, Dede K, Moyer D, Zhou T, Yuan CM, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J Immunother Cancer. 2022;10:e004483.","journal-title":"J Immunother Cancer"},{"key":"2539_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23:86.","journal-title":"Cancer Cell Int"},{"key":"2539_CR92","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced Natural Killer cells in CD19-positive lymphoid tumors. NEJM 2020;382:545\u201353.","journal-title":"NEJM"},{"key":"2539_CR93","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1002\/acg2.84","volume":"3","author":"M Chmielewski","year":"2020","unstructured":"Chmielewski M, Abken H. TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation. Adv Cell Gene Ther. 2020;3:e84.","journal-title":"Adv Cell Gene Ther"},{"key":"2539_CR94","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315.","journal-title":"Blood"},{"key":"2539_CR95","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma. N. Engl J Med. 2022;386:640\u201354.","journal-title":"N. Engl J Med"},{"key":"2539_CR96","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2022","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2022;41:555\u201367.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02539-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:04:35Z","timestamp":1746716675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02539-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02539-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MCV: no COI. MS: no conflict of interest. RdiB: Honoraria for boards, conferences and travellings: Roche, Kyte\/Gilead, Novartis, BMS. CC: no COI. AS Honoraria for boards, conferences and travellings: Roche, Kyte\/Gilead, Novartis, BMS. SC-Z no COI. CT Honoraria for boards, conferences and travellings: Roche, Kyte\/Gilead, Novartis, BMS, Incyte, Amgen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}